Spots Global Cancer Trial Database for NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
Official Title: A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase
Study ID: NCT00248404
Conditions
Interventions
Study Description
Brief Summary: The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of Minnesota, Minneapolis, Minnesota, United States
Princess Margaret Hospital, Toronto, Ontario, Canada
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
